Investors seeking Impact and healthy returns… join us!
We recently closed the first investment round of €1.6 million in March 2023 with a small but highly motivated group of professional and private investors. The funds will be used to prepare and apply for our first clinical trial approval, planning to start by early 2025.
By end of 2024 we aim to raise a Series A of €8 million. With these proceeds we start CT Phase 1/2 pancreatic cancer studies, specifically aiming at border-line resectable PDAC. In parallel we (co-)develop other tumor applications based on the same products.
The planned investment period is 6 years, and we aim to exit as of year 6/7.
Interested to get in touch with us? Please use the contact form in contact page